DONNA

Research Updates

Donna's Journal
January 23rd, 2017
TapImmune Launches Trial

TapImmune, Inc. (NASDAQ: TPIV), a clinical- stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients.
Read More »

Read More »

November 5th, 2016
TapImmune Approved for Listing on the Nasdaq Capital Market

Closer to the Finish! DONNA partner TapImmune announced that its common stock has been approved to begin trading on The Nasdaq Capital Market. The company’s common stock will begin trading under the symbol “TPIV” at the opening of trading on Tuesday, November 8, 2016.

Read More »

November 5th, 2016
TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

Closer to the Finish! DONNA partner TapImmune announces the commercialization pathway for its HER2neu Vaccine and the initiation of company-sponsored Phase 2 Clinical Trials that will start early 2017. In a Phase I clinical trial on the four Class II antigens in HER2neu breast cancer patients performed at the Mayo Clinic.

Read More »

September 19th, 2016
TapImmune Issues Update

Closer to the Finish! DONNA partner TapImmune issued an update to shareholders September 6 announcing the commencement of enrollment of patients in Q4 2016 for the Phase 2 study of TPIV 200 in the treatment of triple negative breast cancer.

Read More »

August 16th, 2016
TapImmune Enters into Definitive Agreements to raise $8.5 Million

DONNA partner TapImmune announced its plans to enter into definitive agreements to raise aggregate gross proceeds of approximately $8.5 million from an approximately $2.5 million private placement transaction with new investors and the exercise of certain outstanding warrants from existing investors that will result in gross proceeds of $6 million.

Read More »

June 22nd, 2016
TapImmune Doses First Patient in its Phase 2 Triple Negative Trial

DONNA partner TapImmune announced a major milestone of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200. The randomized, open label Phase 2 study is expected to enroll a total of 80 subjects. Go Team Go!

Read More »

October 15th, 2015
The Heart Behind the Triple Negative Breast Cancer Trials

ABC TV News Anchor, Laura Harris interviews Dr. Glynn Wilson of Tapimmune Inc., on $13.3 million grant from the US Department of Defense Breast Cancer Research Program to Dr Keith Knutson and Dr Edith Perez at the Mayo Clinic, Jacksonville, FL. This grant will completely fund a large (280 patient) study […]

Read More »

September 15th, 2015
Mayo Clinic receives large federal grant to fund clinical test of innovative triple-negative breast cancer vaccine

“This is just the beginning and it’s why supporting 26.2 with DONNA is so important. We need to continue to fund each of these ideas as they come to our brilliant researchers so we can cure breast cancer.” – Donna Deegan JACKSONVILLE, Fla. — Researchers on Mayo Clinic’s Florida campus have been awarded a $13.3 million, five-year Read More >>

Read More »

Stay Posted

Stay Posted

Locals Rule

Locals Rule

YesWay

YesWay

Team Donna

Team Donna

Donna partners

The Donna Foundation

The Donna Foundation

Jeff Galloway

Jeff Galloway

Mayo Clinic

Mayo Clinic

Learn More

Learn More about 26.2 with Donna Partners